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Objectives. This study was designed to assess the feasibility and 
diagnostic accuracy of dobutamine stress echocardiography for 
detection of coronary artery stenosis in children with Kawasaki 
disease. 
Background. Dobutamine stress echocardiography is valuable 
as an alternative test for detection of coronary artery disease in 
adult patients; however, its usefulness for children has been 
demonstrated only in limited cases. 
Methods. Dobutamine stress echocardiography (up to 30/tg/kg 
body weight per rain) was performed in 50 patients at the 
convalescent stage of Kawasaki disease, including 26 patients with 
coronary sequelae documented by previous coronary angiography 
(sequelae group, 3 to 15 years old) and 24 patients with normal 
coronary arteries documented by eehocardiography (normal 
group, 7 to 16 years old), who underwent quantitative coronary 
angiography on a separate day. Left ventricular egional wall 
motion divided into 16 segments was assessed in relation to the 
extent of coronary artery disease. A positive test response was 
defined as a new or worsened wall motion abnormalities. 
Results. Significant coronary artery disease (>50% diameter 
stenosis of major vessels) was present in 21 patients in the 
sequelae group. There was no significant difference in the maxi- 
mal dose of dobutamine between the sequelae and normal groups 
([mean -+ SD] 22.4 _+ 5.1 vs. 24.2 + 2.5/~g/kg per rain). Heart rate 
and systolic blood pressure were significantly increased (p < 0.01) 
at maximal dose of dobutamine compared with values at rest in 
both groups; consequently, the rate-pressure product exceeded 
20,000 in 20 (40%) of the 50 patients during dobutamine infusion. 
Ten patients had self-limiting side effects; however, there were no 
serious complications from stress-induced ischemia. New wall 
motion abnormalities corresponding to the extent of coronary 
artery disease were detected in 19 of 21 patients in the sequelae 
group, whereas no wall motion abnormalities were detected in the 
normal group. Thus, the sensitivity and specificity of dobutamine 
stress echocardiography for the detection of coronary artery 
disease were 90% and 100%, respectively. 
Conclusions. We conclude that dobutamine stress echocardiog. 
raphy is a safe and accurate diagnostic method for detection of 
coronary artery stenosis in Kawasaki disease. Moreover, this is a 
possible alternative method for patients unable to exercise ade- 
quately, even if they are small children. 
(JAm CoU Cardiol 1996;27:1251-6) 
Stress echocardiography, a relatively new technique for the 
diagnosis of coronary artery disease, is based on the principle 
that stress-induced ischemia results in regional wall motion 
abnormality that can be detected by two-dimensional echocar- 
diography (1-3). More recently, pharmacologic stress echocar- 
diography has been documented as a sensitive and alternative 
stress imaging test, especially in patients unable to perform 
standard treadmill or bicycle exercise (4-7). In adults, stress 
echocardiography now has been reported to be a safe and 
accurate diagnostic method for detection of coronary artery 
disease; however, its usefulness in children has been evaluated 
in only limited cases (8). The purpose of this study was to 
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assess the feasibility and diagnostic accuracy of dobutamine 
stress echocardiography in the evaluation of functional se- 
quelae of coronary artery stenosis in children with Kawasaki 
disease. 
Methods  
Study patients. Between September 1991 and November 
1993, 50 consecutive patients underwent dobutamine stress 
echocardiography for the assessment of progression of coro- 
nary artery aneurysm to stenotic lesion. Twenty-six of the 50 
patients had coronary artery sequelae with Kawasaki disease 
documented by previous coronary angiography (sequelae 
group: 3 to 15 years old, mean age 8.9; number of years since 
initial onset of illness ranged from 2 to 14 years, mean 5.8). 
Among them were 4 patients with left coronary aneurysm, 7
with right coronary aneurysm and 15 with bilateral coronary 
aneurysms. Twenty-four patients had normal coronary arteries 
documented by echocardiography (normal group: 7 to 16 years 
old, mean age 11.2; number of years since initial onset ranged 
©1996 by the American College of Cardiology 0735-1097/96/$15.00 
Published by Elsevier Science Inc. SSDI 0735-1097(95)00570-6 
1252 NOTO ET AL. JACC Vol. 27, No. 5 
DOBUTAMINE IN KAWASAKI DISEASE April 1996:1251-6 
from 3 to 15 years, mean 8.2). These patients had a history of 
regression of coronary ectasia or small coronary aneurysm. 
Twenty-one of the 26 patients in the sequelae group were 
receiving medical therapy: 15 were receiving aspirin only, and 
5 were receiving both aspirin and warfarin for prevention of 
coronary thrombosis. One patient was receiving both beta- 
blocker and calcium channel blocker in addition to aspirin for 
control of sustained ventricular tachycardia. One patient in the 
sequelae group had chest pain accompanied by myocardial 
infarction. The other patients had no symptoms of myocardial 
ischemia. Informed consent to perform dobutamine stress 
echocardiography was obtained from the families of all the 
patients. 
Dobutamine infusion protocol. After 3 h of fasting, an intra- 
venous dobutamine infusion was begun at a dose of 5/xg/kg per 
rain, and the dose was increased every 5 min in 5-/zg/kg steps up 
to 30 Izg/kg per min. Throughout the study, continuous electro- 
cardiographic (ECG) monitoring was performed. Heart rate and 
blood pressure were recorded every minute, and a 12-lead 
standard ECG was recorded at the end of each stage of dobut- 
amine infusion. The dobutamine infusion was terminated for any 
of the following: development of ischemia manifested by new or 
worsening regional wall motion abnormalities demonstrated by
echocardiography; severe chest pain; appearance of complex 
arrhythmia; intolerable side effects, such as headache, palpitation, 
tremor, nausea or vomiting; severe hypertension (systolic blood 
pressure >200 mm Hg or diastolic blood pressure >110 rnm Hg); 
target heart rate (85% of the age-predicted maximal heart rate); 
ST segment depression >2 mm in any lead of the standard ECG, 
or attainment of the maximal dose of dobutamine of30 p~g/kg per 
rain. 
Echocardiographic protocol. With the patients in the left 
lateral decubitus position, two-dimensional echocardiograms 
were obtained with a 2.5- or 3.75-MHz sector scanner (SSH 
65A or SSH 140A, Toshiba). Echocardiograms were continu- 
ously monitored uring each stage of dobutamine infusion. In 
addition to videotape recording, off-line analysis systems 
(Color Cardiology Workstation, TomTec) were used for acqui- 
sition and digital storage of images. Quad-screen images, by 
digital acquisition, of parasternal long-axis, short-axis, apical 
four-chamber and two-chamber views were obtained at rest, at 
low-dose dobutamine infusion (5/xg/kg per rain), at peak-dose 
dobutamine infusion and at recovery. 
Echocardiographic analysis. The wall motion of the left 
ventricle was assessed with a 16-segment model (9). The 
digitized images were independently interpreted by two re- 
viewers unaware of the history and angiographic findings on 
the patients. Discrepancies in the interpretations of the two 
reviewers were resolved by a third reviewer. A normal re- 
sponse to dobutamine infusion was defined as a progressive 
increase in myocardial thickening and hyperdynamic wall 
motion from rest to peak dose of dobutamine infusion. An 
abnormal response to dobutamine infusion was defined as a 
reduction in myocardial thickening or wall motion at any stage 
of the dobutamine infusion compared with the previous tage. 
Segmental wall motion was graded as normal, hypokinetic, 
aldnetic, or dyskinetic. Multivessel disease was defined as 
abnormal wall motion and reduced myocardial thickening 
identified in more than two vascular distribution areas. 
Coronary angiography. All patients underwent left ven- 
triculography and selective coronary angiography a few days 
after the dobutamine stress echocardiography. The locations of 
coronary aneurysms and stenosis were determined according 
to the American Heart Association reporting system (10). 
Quantitative angiographic measurements were performed with 
an edge detection program (10). The percent coronary stenosis 
was calculated with the nearest normal-appearing portion of 
the coronary artery (either distal or proximal to the stenosis) 
used as a standard (11). Significant coronary artery disease was 
defined as 50% or more diameter reduction in major coronary 
arteries. Intercoronary collateral circulation was classified ac- 
cording to the Rentrop grading (ranging from grade 0, no 
visible filling of any collateral channels, to grade 3, complete 
filling of the vessel being dilated) (12); good collateral circu- 
lation was defined as collateral arteries at Rentrop grade 2 or 
higher. 
Statistical analysis. The data are summarized using mean 
values and standard eviations for continuous variables. Mul- 
tiple group comparisons were performed with analysis of 
variance and the Tukey test for individual comparisons within 
groups. A value of p < 0.05 was considered significant. 
Results  
Clinical data. The baseline standard ECG results were 
normal in 49 patients, and the remaining patient had nonspe- 
cific ST-T changes caused by chronic myocardial infarction in 
the right precordial leads. On left ventriculography, no wall 
motion abnormalities were detected in any patient, whereas on 
coronary angiography, significant coronary artery disease was 
present in 21 patients in the sequelae group, including 6 with 
left, 11 with right and 4 with bilateral coronary artery stenosis 
(Table 1). Good intercoronary collateral circulation (Rentrop 
grade ---2) was noted in four patients with right coronary 
obstruction. The other patients presented poor or no visual- 
ization of collateral circulation. 
Dobutamine infusion. Table 2 summarizes the mean values 
of heart rate, systolic blood pressure, rate-pressure product at 
rest and maximal dose of dobutamine infusion. There was no 
significant difference in peak dose of dobutamine between 
the sequelae and normal groups ([mean _+ SD] 22.4 _ 5.1 vs. 
24.2 +_ 2.5 /~g/kg per rain). All variables howed significant 
increases at maximal dose compared with those at rest (p < 
0.01), but there was no significant difference between the 
sequelae and normal groups for any value either at rest or at 
maximal dose. 
During dobutamine infusion, heart rate showed a slight 
linear increase in a dose-dependent manner; consequently, 
heart rate was >140 beats/rain i  23 (46%) of the 50 patients 
at peak dobutamine infusion. In contrast, systolic blood pres- 
sure tended to increase logarithmically up to 30 ~g/kg per rain. 
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Table 1. Clinical Data and Results of Dobutamine Stress Echocardiography in Patients With Significant Coronary Artery Disease 
Coronary Angiography 
Pt Age (yr)/ 
No. Gender WMA on Dobutamine Echo Aneurysm Stenosis (%) 
Collateral 
Circulation 
(Rentrop grade) 
1 ll/F Mid-sept, Mid-inf Bilateral LAD (50%), RCA (100%) 0 
2 ll/F Mid-ant sept Bilateral LAD (thrombus) 1 
3 10/M Mid-inf, Basal-sept RCA RCA (90%) 2 
4 8/M Mid-inf Bilateral RCA (100%) 3 
5 3/M Mid-ant sept, Mid-sept, Mid-inf Bilateral LAD (thrombus), RCA (90%) 1 
6 12fM Mid-lat Cx Cx (50%) 0 
7 9/M ND RCA RCA (90%) 3 
8 10/M Mid-ant sept LAD LAD (50%) 1 
9 15/F ND Bilateral LAD (90%) 1 
10 4/F Mid-inf Bilateral RCA (90%) 0 
11 4/F Mid-inf RCA RCA (50%) 0 
12 ll/M Mid-inf, Basal-sept Bilateral RCA (100%) 3 
13 13/M Mid-inf Bilateral RCA (90%) 1 
14 9/M Mid-ant sept, Apical-sept Bilateral LAD (90%) 0 
15 ll/F Mid-inf Bilateral RCA (100%) 1 
16 ll/F Mid-ant sept, Mid-ant Bilateral LAD (75%) 0 
17 12/M Mid-ant, Mid-inf Bilateral RCA (100%) 1 
18 3/M Mid-ant sept, Mid-ant, Mid-inf Bilateral LAD (50%), RCA (100%) 1 
19 ll/M Mid-ant sept, Mid-ant, Mid-inf Bilateral LAD (50%), RCA (90%) 0 
20 3/M Mid-ant, Mid-sept Bilateral RCA (90%) 0 
21 9/M Mid-ant sept, Mid-ant, Mid-inf Bilateral RCA (100%) 1 
Apical-sept = apical septum; Basal-sept = basal septum; Cx = circumflex coronary artery; Echo = echocardiography; F = female; LAD = left anterior descending 
coronary artery; M = male; Mid-ant = midanterior; Mid-ant sept = midanterior septum; Mid-inf = midinferior; Mid-lat = midlateral; Mid-sept = midseptum; Pt = 
patient; RCA = right coronary artery; WMA = wall motion abnormalities. 
As a result, rate-pressure product was >20,000 in 20 (40%) of 
the 50 patients at peak dobutamine infusion. 
Ten (20%) of the patients developed side effects during 
dobutamine stress echocardiography that included headache in 
four, premature atrial contraction in three, palpitation in two 
and nausea in one. These side effects were self-limiting and 
resolved spontaneously with discontinuation of the infusion. 
No patient developed premature ventricular contraction or 
ventricular tachycardia during dobutamine infusion. 
The reasons for termination of dobutamine stress echocar- 
diography were reaching the maximal dose of 30/xg/kg per min 
in 25 patients (50%), stress-induced wall motion abnormalities 
in 19 (38%), headache in 2 (4%), hypertension (systolic blood 
pressure ->200 mm Hg) in 2 (4%) and target heart rate and 
palpitation in one (2%) each. Although the test protocol could 
not be completed because of limiting side effects in three 
patients (headache in two, palpitation in one), most patients 
tolerated the dobutamine infusion well. 
Feasibility analysis. All patients were in stable condition 
during dobutamine infusion, and good quality echocardio- 
grams were obtained. Minimal discrepancy in interpretation by 
the two reviewers of whether wall motion abnormalities were 
present was noted for the echocardiograms in two patients 
(4%). Localized rest wall motion abnormalities of the mid- 
inferior segment was detected in one patient who had chronic 
myocardial infarction. Stress-induced wall motion abnormali- 
ties corresponding to the distribution of coronary artery dis- 
ease were detected in 19 of 21 patients in the sequelae group. 
No such abnormalities, however, were detected in the normal 
group. In an analysis according to the number of affected 
vessels, single-vessel disease was detected in 15 (88%) of 17 
patients, and multivessel disease was detected in 4 (100%) of 4 
patients on dobutamine stress echocardiography. False- 
negative findings were observed in two patients, one of whom 
had significant coronary artery disease in the left main coro- 
nary artery and was receiving beta-adrenergic blocking therapy 
Table 2. Hemodynamic Findings During Dobutamine Infusion 
Sequelae Group (mean -- SD) 
Rest Maximal Dose 
Normal Group (mean _+ SD) 
Rest Maximal Dose 
Heart rate (beats/min) 81.0 _+ 11.8 128.1 _+ 21.3' 81.5 + 18.1 135.1 _+ 21.1' 
Systolic BP (ram Hg) 96.8 _+ 15.2 147.5 _+ 21.8' 105.5 -* 15.7 153.5 _+ 25.4* 
Rate-pressure product (/1,000) 7.9 + 1.4 18.5 _+ 3.5* 8.7 _* 2.3 21.1 _+ 3.7* 
*p < 0.01 versus Rest. BP = blood pressure. 
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Figure 1. Basal (BASE) and peak dose (PEAK D) dobutamine stress 
echocardiographic images of short-axis (SAX) and four-chamber (4C) 
views obtained ina patient with bilateral coronary aneurysms. At rest, 
asynergy is not visible. At peak dose, midseptal dyskinesia and 
midinferior akinesia re present (arrows). E-D = end-diastole; E-S = 
end-systole. 
for control of sustained ventricular tachycardia, nd the other 
had right coronary artery obstruction with sufficient collateral 
circulation from the circumflex coronary artery to the distal 
portion of the obstructive l sion. There were no false-positive 
findings in either group. Thus, the overall sensitivity and 
specificity of dobutamine stress echoeardiography correspond- 
ing to the extent of coronary artery disease was 90% and 100%, 
respectively (Fig. 1 and 2). 
Discuss ion  
Fate of coronary aneurysms. Coronary artery abnormali- 
ties develop in -20% of children with untreated Kawasaki 
disease. Recently, it was revealed that intravenous gamma- 
globulin therapy instituted at the early stage of illness reduced 
both the morbidity of Kawasald disease and the apparent 
incidence of coronary artery abnormalities. Coronary artery 
aneurysm, however, occurs in -5% of patients receiving 
intravenous gamma-globulin and aspirin therapy (11,13,14), 
and it often leads to obstructive or stenotic lesions, especially 
in patients with giant coronary aneurysms (maximal diameter 
Figure 2. Coronary angiograms from the same patient as in Figure 1 
reveal 75% stenosis of the left anterior descending coronary artery 
(LAD) (arrow) and obvious right coronary artery obstruction (RCA). 
CX = circumflex coronary artery. 
>-8 mm) at the convalescent s age (15). Myocardial ischemia 
may occur in such patients, in whom higher risk of sudden 
death may also occur. Therefore, it is desirable to screen for 
the progression of coronary aneurysm to stenotic lesions. In 
this application, coronary angiography is an accurate method 
of evaluating coronary artery involvement (13). This method, 
however, cannot be applied repeatedly. Moreover, the coro- 
nary angiography findings reflect only the status of the free 
cavity of the coronary aneurysm but not that of the original 
aneurysm. In contrast, two-dimensional echocardiography dis-
closes an echo-free space representing the original aneurysm, 
in which some materials uggesting thrombi or organization 
are seen. However, it does not clearly reveal whether the 
aneurysm is occlusive (16). 
Myocardial scintigraphy with pharmacologic stress has been 
reported to be useful in adult patients (17,18), but there are 
some clinical limitations of scintigraphy in children, among 
them the relatively poor spatial resolution, modest specificity, 
exposure to radiation, necessity for sedation of younger chil- 
dren, and long time required to obtain the data (19). Recently, 
pharmacologic stress echocardiography hascome to be seen as 
an alternative to scintigraphy in the detection of coronary 
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stenotic lesions in adult patients (6,7,20,21), but the data for 
children are limited (8). 
Rationale of dobutamine stress echocardiography. Dobut- 
amine is a synthetic atecholamine that acts predominantly as 
a beta-l-receptor agonist. ~:fter the increment of dobutamine 
infusion, cardiac output is increased by augmentation of 
myocardial contractility and by an increase in heart rate, 
resulting in an increase in myocardial oxygen demand. Myo- 
cardial ischemia will be induced if the coronary flow reserve is 
inadequate to meet the increase in demand (22). Heart rate is 
thought o be one of the major determinant factors relating to 
oxygen consumption i induced myocardial ischemia. Recently 
there have been some trials in dobutamine stress echocardiog- 
raphy to obtain the target heart rate by using high dose 
dobutamine infusion (>30 /~g/kg per min) in addition to 
atropine infusion (23,24) in attempts to provoke greater myo- 
cardial stress and subsequent ischemia by increasing the value 
of the rate-pressure product. According to the present results, 
the heart rate tended to increase linearly, and subsequently it 
was possible to obtain a rate-pressure product >20,000 in 40% 
of patients at peak dobutamine infusion. Compared with 
previous studies using high doses of dobutamine infusion in 
adult patients (6,20,25,26), in which the heart rate reached at 
most 120 to 130 beats/rain at peak dose, our study revealed that 
a response pattern of the heart rate in a manner similar to that 
in exercise might account for the higher sensitivity and greater 
suitability of dobutamine stress echocardiography for children 
than for adult patients. 
False-negative studies. The instances of false-negative do- 
butamine stress echocardiography occurred mainly in our 
study patients who were either receiving a beta-blocker or 
presented sufficient collateral circulation distal to the obstruc- 
tive lesions. A recent report indicated that the sensitivity of the 
stress echocardiography was not affected by beta-blocker ad- 
ministration (6). Although our patients had reduced peak 
heart rate and rate-pressure product compared with those not 
receiving beta-blocker, one would expect that myocardial 
ischemia was not induced by an attenuated heart rate response. 
Moreover, it is conceivable that sufficient collateral circulation 
in coronary angiograms may protect against myocardial isch- 
emia induced by dobutamine infusion, but no clear correlation 
between a false-negative r sult and quantitative assessment of
collateral circulation was discernible. 
Relevance of side effects. The progressive infusion of dobut- 
amine used in this study was generally well tolerated. A previous 
report suggested that dobutamine may be dangerous in patients 
with coronary artery disease because it frequently induces malig- 
nant ventricular arrhythmia (26). During the dobutamine infu- 
sion, no significant arrhythmias occurred that would have require 
termination of infusion. This finding indicates that although 
dobutamine undoubtly has an arrhythmogenic potential, it is safer 
in children than among adult patients (27). 
Study limitations. 1) One potential limitation of this study 
is the subjective, nonquantitative analysis of the echocardio- 
graphic images. Qualitative analysis, however, was found to be 
accurate and reproducible by the use of digital acquisition of 
images, which provided high sensitivity and specificity for 
detection of coronary artery disease. 2) The optimal dose of 
dobutamine infusion in children is not clear. Whether a more 
aggressive infusion protocol would enhance the diagnostic 
value without imposing additional side effects is an issue for 
ongoing investigation. Further studies in a larger, unselected 
patient population are necessary to assess the advantages and 
limitations of this test in the diagnosis of coronary artery 
disease in Kawasaki disease. 
Conclusions. To date, although no actual cause of Ka- 
wasaki disease has been documented, it is certain that early 
detection of myocardial ischemia and its management would 
be one of the major problems in long-term follow-up of 
patients with cardiac involvement. Our study disclosed that 
dobutamine stress echocardiography is a promising new 
method for assessing the functional significance of coronary 
lesions, even if they are not depicted as significant by two- 
dimensional echocardiography. 
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